WuXi Biologics (Cayman) Inc $ 37.67 1.04 (2.84%)
Volume:
7,126
Avg Vol (1m):
30,552
Market Cap $:
25.52 Bil
Enterprise Value $:
24.88 Bil
P/E (TTM):
171.10
P/B:
13.65
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.08 | ||
| Equity-to-Asset | 0.73 | ||
| Debt-to-Equity | 0.17 | ||
| Debt-to-EBITDA | 1.9 | ||
| Interest Coverage | 54.13 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 19.09 | ||
| Beneish M-Score | -2.26 | ||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 26.55 | ||
| Net Margin % | 25.47 | ||
| ROE % | 10.35 | ||
| ROA % | 8.16 | ||
| ROC (Joel Greenblatt) % | 22.41 | ||
| 3-Year Revenue Growth Rate | 50.4 | ||
| 3-Year EBITDA Growth Rate | 57.9 | ||
| 3-Year EPS without NRI Growth Rate | 82.5 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 171.1 | ||
| Forward PE Ratio | 149.25 | ||
| PE Ratio without NRI | 171.1 | ||
| Price-to-Owner-Earnings | 406.36 | ||
| PB Ratio | 13.65 | ||
| PS Ratio | 43.53 | ||
| Price-to-Operating-Cash-Flow | 144.2 | ||
| EV-to-EBIT | 143.67 | ||
| EV-to-EBITDA | 143.67 | ||
| EV-to-Revenue | 41.34 | ||
| PEG Ratio | 2.18 | ||
| Current Ratio | 3.37 | ||
| Quick Ratio | 3.23 | ||
| Days Inventory | 49.66 | ||
| Days Sales Outstanding | 121.32 | ||
| Days Payable | 28.94 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 14.38 | ||
| Price-to-Peter-Lynch-Fair-Value | 6.9 | ||
| Price-to-Graham-Number | 10.43 | ||
| Earnings Yield (Greenblatt) % | 0.66 | ||
| Forward Rate of Return (Yacktman) % | 19.51 |